Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism
Pharmaceutics · 22.05.2025 · 17 (6) · 680
DOI: 10.3390/pharmaceutics17060680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.05.2025. Verfasst von Melissa van Deventer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), Building G16, Faculty of Health Sciences, North-West University, Potchefstroom 2520, …. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SA NRF, South African National Research Foundation (SA NRF).
Abstract (Originalsprache)
Background
Tuberculosis remains a significant global health issue, and the rise of drug-resistant strains is becoming increasingly concerning. Currently, treatment options are limited to systemic regimens; however, developing topical drug delivery systems could offer advantages for treating cutaneous tuberculosis (CTB) when applied directly to the lesions. We developed topical emulsions using the self-emulsification mechanism that combine fixed doses of isoniazid (INH) and rifampicin (RIF) using a quality-by-design approach.
Methods
Preformulation studies pertaining to drug solubility in various solvents, the construction of pseudoternary diagrams to identify self-emulsification regions for each tested excipient combination, and the preparation of checkpoint formulations were conducted and visually examined. Formulations displaying no physical instabilities were subsequently exposed to characterization experiments, including droplet size determination, zeta potential, size distribution, viscosity, pH, self-emulsification, cloud point, robustness to dilution, and thermodynamic stability assessment. Three selected formulations were consequently subjected to membrane release experiments, followed by skin diffusion studies, and INH and RIF stability in these emulsions was determined, because these drugs have a known interaction.
Conclusions
While incorporating essential oils in a topical formulation improved RIF solubility, it also resulted in several instabilities. RIF exhibited greater susceptibility to degradation under higher temperatures and lower pH conditions. However, drug release from all formulations tested was confirmed. Notably, olive oil microemulsions demonstrated the most favorable characteristics for dermal drug delivery; nonetheless, drug diffusion into and through the skin (which was not desired) could not be quantified. Despite these challenges, the findings indicate that topical drug delivery systems using the self-emulsification process can facilitate the direct treatment of CTB.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), Building G16, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa.
- Rural Health Research Institute, Charles Sturt University, Orange, NSW 2800, Australia.
ORCID-Profile: Melissa van Deventer, Richard K Haynes, Joe M Viljoen
Förderung
- SA NRF
- South African National Research Foundation (SA NRF)
Zitieren
APA
van Deventer, M., Haynes, R. K., Brits, M., & Viljoen, J. M. (2025). Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism. Pharmaceutics, 17(6), 680. https://doi.org/10.3390/pharmaceutics17060680
Vancouver
van Deventer M, Haynes RK, Brits M, Viljoen JM. Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism. Pharmaceutics. 2025;17(6):680. doi:10.3390/pharmaceutics17060680
BibTeX
@article{vanDeventer2025,
author = {van Deventer, Melissa and Haynes, Richard K and Brits, Marius and Viljoen, Joe M},
title = {Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {6},
pages = {680},
doi = {10.3390/pharmaceutics17060680}
}
EUVIMED